Davalintide (AC2307), a novel amylin-mimetic peptide

Enhanced pharmacological properties over native amylin to reduce food intake and body weight

C. M. MacK, C. J. Soares, J. K. Wilson, J. R. Athanacio, V. F. Turek, J. L. Trevaskis, J. D. Roth, P. A. Smith, B. Gedulin, C. M. Jodka, B. L. Roland, S. H. Adams, A. Lwin, J. Herich, K. D. Laugero, C. Vu, R. Pittner, J. R. Paterniti, M. Hanley, S. Ghosh & 1 others D. G. Parkes

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective: The current set of studies describe the in vivo metabolic actions of the novel amylin-mimetic peptide davalintide (AC2307) in rodents and compares these effects with those of the native peptide.Research design and methods: The anti-obesity effects of davalintide were examined after intraperitoneal injection or sustained peripheral infusion through subcutaneously implanted osmotic pumps. The effect of davalintide on food intake after lesioning of the area postrema (AP) and neuronal activation as measured by c-Fos, were also investigated.Results: Similar to amylin, davalintide bound with high affinity to amylin, calcitonin and calcitonin gene-related peptide receptors. Acutely, davalintide displayed greater suppression of dark-cycle feeding and an extended duration of action compared with amylin (23 versus 6 h). Davalintide had no effect on locomotor activity or kaolin consumption at doses that decreased food intake. Davalintide-induced weight loss through infusion was dose dependent, durable up to 8 weeks, fat-specific and lean-sparing, and was associated with a shift in food preference away from high-fat (palatable) chow. Metabolic rate was maintained during active weight loss. Both davalintide and amylin failed to suppress food intake after lesioning of the AP and activated similar brain nuclei, with davalintide displaying an extended duration of c-Fos expression compared with amylin (8 versus 2 h).Conclusion: Davalintide displayed enhanced in vivo metabolic activity over amylin while retaining the beneficial properties possessed by the native molecule. In vitro receptor binding, c-Fos expression and AP lesion studies suggest that the metabolic actions of davalintide and amylin occur through activation of similar neuronal pathways.

Original languageEnglish (US)
Pages (from-to)385-395
Number of pages11
JournalInternational Journal of Obesity
Volume34
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Islet Amyloid Polypeptide
Eating
Body Weight
Pharmacology
Peptides
Area Postrema
davalintide
Amylin Receptor Agonists
Weight Loss
Fats
Calcitonin Gene-Related Peptide Receptors
Kaolin
Food Preferences
Calcitonin
Locomotion
Intraperitoneal Injections
Rodentia

Keywords

  • AC2307
  • Amylin
  • Area postrema
  • Body weight
  • Davalintide
  • Food intake

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Davalintide (AC2307), a novel amylin-mimetic peptide : Enhanced pharmacological properties over native amylin to reduce food intake and body weight. / MacK, C. M.; Soares, C. J.; Wilson, J. K.; Athanacio, J. R.; Turek, V. F.; Trevaskis, J. L.; Roth, J. D.; Smith, P. A.; Gedulin, B.; Jodka, C. M.; Roland, B. L.; Adams, S. H.; Lwin, A.; Herich, J.; Laugero, K. D.; Vu, C.; Pittner, R.; Paterniti, J. R.; Hanley, M.; Ghosh, S.; Parkes, D. G.

In: International Journal of Obesity, Vol. 34, No. 2, 02.2010, p. 385-395.

Research output: Contribution to journalArticle

MacK, CM, Soares, CJ, Wilson, JK, Athanacio, JR, Turek, VF, Trevaskis, JL, Roth, JD, Smith, PA, Gedulin, B, Jodka, CM, Roland, BL, Adams, SH, Lwin, A, Herich, J, Laugero, KD, Vu, C, Pittner, R, Paterniti, JR, Hanley, M, Ghosh, S & Parkes, DG 2010, 'Davalintide (AC2307), a novel amylin-mimetic peptide: Enhanced pharmacological properties over native amylin to reduce food intake and body weight', International Journal of Obesity, vol. 34, no. 2, pp. 385-395. https://doi.org/10.1038/ijo.2009.238
MacK, C. M. ; Soares, C. J. ; Wilson, J. K. ; Athanacio, J. R. ; Turek, V. F. ; Trevaskis, J. L. ; Roth, J. D. ; Smith, P. A. ; Gedulin, B. ; Jodka, C. M. ; Roland, B. L. ; Adams, S. H. ; Lwin, A. ; Herich, J. ; Laugero, K. D. ; Vu, C. ; Pittner, R. ; Paterniti, J. R. ; Hanley, M. ; Ghosh, S. ; Parkes, D. G. / Davalintide (AC2307), a novel amylin-mimetic peptide : Enhanced pharmacological properties over native amylin to reduce food intake and body weight. In: International Journal of Obesity. 2010 ; Vol. 34, No. 2. pp. 385-395.
@article{4295b99d1bcc4f9581911ff6a221d9d8,
title = "Davalintide (AC2307), a novel amylin-mimetic peptide: Enhanced pharmacological properties over native amylin to reduce food intake and body weight",
abstract = "Objective: The current set of studies describe the in vivo metabolic actions of the novel amylin-mimetic peptide davalintide (AC2307) in rodents and compares these effects with those of the native peptide.Research design and methods: The anti-obesity effects of davalintide were examined after intraperitoneal injection or sustained peripheral infusion through subcutaneously implanted osmotic pumps. The effect of davalintide on food intake after lesioning of the area postrema (AP) and neuronal activation as measured by c-Fos, were also investigated.Results: Similar to amylin, davalintide bound with high affinity to amylin, calcitonin and calcitonin gene-related peptide receptors. Acutely, davalintide displayed greater suppression of dark-cycle feeding and an extended duration of action compared with amylin (23 versus 6 h). Davalintide had no effect on locomotor activity or kaolin consumption at doses that decreased food intake. Davalintide-induced weight loss through infusion was dose dependent, durable up to 8 weeks, fat-specific and lean-sparing, and was associated with a shift in food preference away from high-fat (palatable) chow. Metabolic rate was maintained during active weight loss. Both davalintide and amylin failed to suppress food intake after lesioning of the AP and activated similar brain nuclei, with davalintide displaying an extended duration of c-Fos expression compared with amylin (8 versus 2 h).Conclusion: Davalintide displayed enhanced in vivo metabolic activity over amylin while retaining the beneficial properties possessed by the native molecule. In vitro receptor binding, c-Fos expression and AP lesion studies suggest that the metabolic actions of davalintide and amylin occur through activation of similar neuronal pathways.",
keywords = "AC2307, Amylin, Area postrema, Body weight, Davalintide, Food intake",
author = "MacK, {C. M.} and Soares, {C. J.} and Wilson, {J. K.} and Athanacio, {J. R.} and Turek, {V. F.} and Trevaskis, {J. L.} and Roth, {J. D.} and Smith, {P. A.} and B. Gedulin and Jodka, {C. M.} and Roland, {B. L.} and Adams, {S. H.} and A. Lwin and J. Herich and Laugero, {K. D.} and C. Vu and R. Pittner and Paterniti, {J. R.} and M. Hanley and S. Ghosh and Parkes, {D. G.}",
year = "2010",
month = "2",
doi = "10.1038/ijo.2009.238",
language = "English (US)",
volume = "34",
pages = "385--395",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Davalintide (AC2307), a novel amylin-mimetic peptide

T2 - Enhanced pharmacological properties over native amylin to reduce food intake and body weight

AU - MacK, C. M.

AU - Soares, C. J.

AU - Wilson, J. K.

AU - Athanacio, J. R.

AU - Turek, V. F.

AU - Trevaskis, J. L.

AU - Roth, J. D.

AU - Smith, P. A.

AU - Gedulin, B.

AU - Jodka, C. M.

AU - Roland, B. L.

AU - Adams, S. H.

AU - Lwin, A.

AU - Herich, J.

AU - Laugero, K. D.

AU - Vu, C.

AU - Pittner, R.

AU - Paterniti, J. R.

AU - Hanley, M.

AU - Ghosh, S.

AU - Parkes, D. G.

PY - 2010/2

Y1 - 2010/2

N2 - Objective: The current set of studies describe the in vivo metabolic actions of the novel amylin-mimetic peptide davalintide (AC2307) in rodents and compares these effects with those of the native peptide.Research design and methods: The anti-obesity effects of davalintide were examined after intraperitoneal injection or sustained peripheral infusion through subcutaneously implanted osmotic pumps. The effect of davalintide on food intake after lesioning of the area postrema (AP) and neuronal activation as measured by c-Fos, were also investigated.Results: Similar to amylin, davalintide bound with high affinity to amylin, calcitonin and calcitonin gene-related peptide receptors. Acutely, davalintide displayed greater suppression of dark-cycle feeding and an extended duration of action compared with amylin (23 versus 6 h). Davalintide had no effect on locomotor activity or kaolin consumption at doses that decreased food intake. Davalintide-induced weight loss through infusion was dose dependent, durable up to 8 weeks, fat-specific and lean-sparing, and was associated with a shift in food preference away from high-fat (palatable) chow. Metabolic rate was maintained during active weight loss. Both davalintide and amylin failed to suppress food intake after lesioning of the AP and activated similar brain nuclei, with davalintide displaying an extended duration of c-Fos expression compared with amylin (8 versus 2 h).Conclusion: Davalintide displayed enhanced in vivo metabolic activity over amylin while retaining the beneficial properties possessed by the native molecule. In vitro receptor binding, c-Fos expression and AP lesion studies suggest that the metabolic actions of davalintide and amylin occur through activation of similar neuronal pathways.

AB - Objective: The current set of studies describe the in vivo metabolic actions of the novel amylin-mimetic peptide davalintide (AC2307) in rodents and compares these effects with those of the native peptide.Research design and methods: The anti-obesity effects of davalintide were examined after intraperitoneal injection or sustained peripheral infusion through subcutaneously implanted osmotic pumps. The effect of davalintide on food intake after lesioning of the area postrema (AP) and neuronal activation as measured by c-Fos, were also investigated.Results: Similar to amylin, davalintide bound with high affinity to amylin, calcitonin and calcitonin gene-related peptide receptors. Acutely, davalintide displayed greater suppression of dark-cycle feeding and an extended duration of action compared with amylin (23 versus 6 h). Davalintide had no effect on locomotor activity or kaolin consumption at doses that decreased food intake. Davalintide-induced weight loss through infusion was dose dependent, durable up to 8 weeks, fat-specific and lean-sparing, and was associated with a shift in food preference away from high-fat (palatable) chow. Metabolic rate was maintained during active weight loss. Both davalintide and amylin failed to suppress food intake after lesioning of the AP and activated similar brain nuclei, with davalintide displaying an extended duration of c-Fos expression compared with amylin (8 versus 2 h).Conclusion: Davalintide displayed enhanced in vivo metabolic activity over amylin while retaining the beneficial properties possessed by the native molecule. In vitro receptor binding, c-Fos expression and AP lesion studies suggest that the metabolic actions of davalintide and amylin occur through activation of similar neuronal pathways.

KW - AC2307

KW - Amylin

KW - Area postrema

KW - Body weight

KW - Davalintide

KW - Food intake

UR - http://www.scopus.com/inward/record.url?scp=76749086899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749086899&partnerID=8YFLogxK

U2 - 10.1038/ijo.2009.238

DO - 10.1038/ijo.2009.238

M3 - Article

VL - 34

SP - 385

EP - 395

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 2

ER -